Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$12.62 USD
+0.36 (2.89%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $12.73 +0.11 (0.87%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Intellia Therapeutics, Inc. has a market cap of $1.32B, which represents its share price of $12.27 multiplied by its outstanding shares number of 107.35M. As a small-cap company, NTLA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NTLA 12.62 +0.36(2.89%)
Will NTLA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for NTLA
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Other News for NTLA
PLTR, KTOS, BLSH, NTLA: Cathie Wood Trims Stakes in Palantir and Kratos Defense, Doubles Down on Intellia
Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)
Is NTLA preparing to trend lower? Lower Bollinger Band Walk shows up after rising 2.89%
DoorDash, Microsoft, Intellia, Upwork, Qorvo: Trending by Analysts
SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA